Preprint Case Report Version 2 Preserved in Portico This version is not peer-reviewed

Systemic Lupus Erythematosus and Its Treatment With Intravenous Immunoglobulins (IVIG)

Version 1 : Received: 21 September 2020 / Approved: 23 September 2020 / Online: 23 September 2020 (08:05:06 CEST)
Version 2 : Received: 23 April 2021 / Approved: 23 April 2021 / Online: 23 April 2021 (09:48:40 CEST)

How to cite: Justiz Vaillant, A.; Ferrer Cosme, B. Systemic Lupus Erythematosus and Its Treatment With Intravenous Immunoglobulins (IVIG). Preprints 2020, 2020090544 (doi: 10.20944/preprints202009.0544.v2). Justiz Vaillant, A.; Ferrer Cosme, B. Systemic Lupus Erythematosus and Its Treatment With Intravenous Immunoglobulins (IVIG). Preprints 2020, 2020090544 (doi: 10.20944/preprints202009.0544.v2).

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by a broad array of clinical signs. In this study, we aimed to use intravenous immunoglobulins (IVIG), called intacglobin, as a monotherapy to manage SLE in three patients. Laboratory investigations for SLE diagnosis were performed, including the detection of anti-nuclear antibodies (ANA) and SLE confirmation by detecting high titers of anti-dsDNA antibodies. C3 and C4 serum levels were assessed, as well as the determination of immunoglobulins. The SLEDAI score was measured to determine whether a significant degree of disease activity existed and as a prognostic value. The evaluation of any chest infection was performed by chest-X-ray. The patients were treated with five–ten g/day of IVIG for six consecutive days, followed by five–ten g/month. Immunological evaluation demonstrated that patients presented with a flare of SLE with high titers of ANA and anti-dsDNA antibodies, low C3 and C4, and elevated immunoglobulin levels. The SLEDAI score falls from 10 to below 3, and chest infections in some patients are cleared up. The postulated mechanisms of action of IVIG demonstrated that it could be used as an immunosuppressor, immunomodulator, and antimicrobial agent in patients with SLE.

Keywords

Systemic lupus erythematosus (SLE); Intravenous immunoglobulins (IVIG); Autoantibody; Autoimmune disease; Pneumonia

Comments (1)

Comment 1
Received: 23 April 2021
Commenter: Angel Justiz Vaillant
Commenter's Conflict of Interests: Author
Comment: I added two new cases of systemic lupus erythematosus treated successfully with intravenous immunoglobulins.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.